Ian F. Tannock

Q: What Schools Are Affiliated With Ian F. Tannock

Ian F. Tannock is affiliated with the following schools: Université de Montréal, University of Sydney, University of British Columbia, McMaster University, University of Toronto

Ian F. Tannock's AcademicInfluence.com Rankings

Ian F. Tannock

Medical

#587

World Rank

#791

Historical Rank

Oncology

#15

World Rank

#16

Historical Rank

medical Degrees

Ian F. Tannock

Philosophy

#2430

World Rank

#4161

Historical Rank

Logic

#580

World Rank

#1043

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Ian F. Tannock Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ian F. Tannock's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (2004) (5412)
Drug penetration in solid tumours (2006) (2370)
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. (2014) (2129)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008) (2023)
Drug resistance and the solid tumor microenvironment. (2007) (1852)
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. (1996) (1595)
Acid pH in tumors and its potential for therapeutic exploitation. (1989) (1592)
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer (2000) (1145)
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial (2014) (1129)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. (2008) (1061)
Measuring health-related quality of life. (1999) (969)
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. (1992) (710)
Delivering affordable cancer care in high-income countries. (2011) (656)
Repopulation of cancer cells during therapy: an important cause of treatment failure (2005) (656)
The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. (1968) (617)
The Basic Science of Oncology (1989) (587)
Cognitive function in breast cancer patients receiving adjuvant chemotherapy. (2000) (549)
Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis (2014) (521)
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial (2002) (514)
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. (1997) (486)
Cytokines and their relationship to the symptoms and outcome of cancer (2008) (484)
Bone metastases: pathophysiology and management policy. (1991) (471)
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. (2002) (463)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. (2018) (452)
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. (1996) (446)
Effectiveness of specialized palliative care: a systematic review. (2008) (440)
Cognitive impairment associated with chemotherapy for cancer: report of a workshop. (2004) (432)
The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors (2005) (430)
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. (1989) (404)
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. (2012) (400)
A critical appraisal of the "human tumor stem-cell assay". (1983) (386)
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. (2003) (380)
A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis (2007) (359)
Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence (2014) (348)
A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. (1988) (326)
Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. (2008) (324)
Limits to Personalized Cancer Medicine. (2016) (316)
Factors associated with failure to publish large randomized trials presented at an oncology meeting. (2003) (304)
Drug resistance in metastatic castration-resistant prostate cancer (2011) (296)
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. (2005) (288)
Prostate cancer (2016) (288)
Potential drug interactions and duplicate prescriptions among cancer patients. (2007) (287)
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. (2016) (281)
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. (2014) (280)
Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. (1972) (279)
Perception of quality of life by patients, partners and treating physicians (2004) (270)
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. (2007) (269)
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. (2013) (268)
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. (1997) (265)
Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. (1970) (260)
Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. (2007) (260)
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. (2003) (256)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (2015) (256)
Perceptions of palliative care among patients with advanced cancer and their caregivers (2016) (255)
Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. (2014) (255)
The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour (1968) (255)
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. (2010) (252)
ON THE EXISTENCE OF A Go‐PHASE IN THE CELL CYCLE (1970) (244)
Cell kinetics and chemotherapy: a critical review. (1978) (228)
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. (1999) (227)
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. (1999) (223)
The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. (2006) (210)
The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. (1998) (209)
Cognitive function after chemotherapy in adults with solid tumours. (2007) (201)
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy (2005) (201)
The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice (2006) (201)
Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. (1993) (200)
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer (2009) (197)
MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. (2011) (188)
Requirement of the Na+/H+ exchanger for tumor growth. (1989) (180)
A comparison of the relative efficiencies of various metaphase arrest agents (1967) (178)
Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. (2006) (176)
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. (2005) (175)
The proliferation of capillary endothelial cells. (1972) (175)
Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? (1985) (167)
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer (2008) (167)
Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. (2015) (165)
Predictive model for survival in patients with advanced cancer. (2008) (165)
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. (1994) (160)
How expert physicians would wish to be treated if they had genitourinary cancer. (1988) (159)
Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. (2015) (158)
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. (2010) (157)
New therapies for castration-resistant prostate cancer: efficacy and safety. (2011) (156)
Quantitative techniques for study of the anatomy and function of small blood vessels in tumors. (1969) (152)
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. (1984) (150)
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. (2014) (147)
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. (2012) (146)
Combined modality treatment with radiotherapy and chemotherapy. (1989) (145)
The fate of abstracts submitted to a cancer meeting: factors which influence presentation and subsequent publication. (1992) (145)
Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: potential implications for cell death in tumors. (1986) (143)
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. (1989) (143)
Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. (1999) (141)
Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio (2014) (139)
Evolution of the randomized controlled trial in oncology over three decades. (2008) (139)
Preclinical development of molecular-targeted agents for cancer (2011) (137)
Assessing cognitive function in cancer patients (2006) (137)
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma (2001) (135)
Treatment of cancer with radiation and drugs. (1996) (135)
Tumor Physiology and Drug Resistance (2004) (135)
Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment (2006) (134)
A comparison of cell proliferation parameters in solid and ascites Ehrlich tumors. (1969) (133)
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors (2010) (133)
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. (1997) (133)
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. (2010) (132)
Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. (1983) (128)
Influence of vitamin A on immunological response. (1972) (128)
Conventional cancer therapy: promise broken or promise delayed? (1998) (127)
Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. (1992) (122)
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. (2013) (121)
Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer. (1986) (121)
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. (2013) (118)
Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. (1981) (117)
Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. (2007) (116)
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. (2008) (115)
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? (2013) (114)
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. (2012) (113)
High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. (1998) (113)
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. (2015) (113)
When are "positive" clinical trials in oncology truly positive? (2011) (112)
Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. (2010) (112)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (110)
Placebo effects in oncology. (2003) (109)
Cytotoxicity of compounds that interfere with the regulation of intracellular pH: a potential new class of anticancer drugs. (1987) (105)
Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. (2007) (104)
Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. (1998) (102)
Cognitive function and fatigue after diagnosis of colorectal cancer. (2014) (102)
Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. (2013) (102)
Management of advanced prostate cancer after first-line chemotherapy. (2005) (101)
Cell proliferation in human melanoma. (1970) (100)
Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration (2006) (99)
Sequential chemotherapy and radiation for nasopharyngeal cancer: absence of long-term benefit despite a high rate of tumor response to chemotherapy. (1987) (98)
The Tumor Microenvironment and Strategies to Improve Drug Distribution (2013) (97)
Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. (2011) (97)
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. (1999) (96)
Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interaction of the drugs with radiation. (1982) (93)
A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. (2002) (93)
Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the princess margaret hospital experience (1991) (92)
The role of kinin receptors in cancer and therapeutic opportunities. (2014) (91)
False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons. (1996) (91)
Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. (2011) (90)
Phase II Trial of Mirtazapine for Cancer-Related Cachexia and Anorexia (2010) (90)
Reduction of intracellular pH as a possible mechanism for killing cells in acidic regions of solid tumors: effects of carbonylcyanide-3-chlorophenylhydrazone. (1989) (86)
Determinants of quality of life in patients with advanced cancer (2011) (86)
Perioperative chemotherapy for muscle‐invasive bladder cancer: A population‐based outcomes study (2014) (85)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (85)
Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. (2017) (85)
The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. (1996) (84)
The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. (1998) (84)
Low‐dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design (2004) (83)
Human Tumor Stem-Cell Assay (1983) (83)
Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors12 (2016) (82)
Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. (1990) (82)
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. (1998) (82)
Chemotherapy with gemcitabine‐containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma (2002) (81)
Chemotherapy-based treatment for castration-resistant prostate cancer. (2011) (81)
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. (2014) (79)
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium (2011) (79)
Death of tumor cells after intracellular acidification is dependent on stress-activated protein kinases (SAPK/JNK) pathway activation and cannot be inhibited by Bcl-2 expression or interleukin 1beta-converting enzyme inhibition. (1998) (78)
Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? (2012) (78)
Therapeutic potential of analogues of amiloride: inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy. (1993) (77)
Outcomes and endpoints in cancer trials: bridging the divide. (2015) (75)
Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. (1998) (74)
Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment. (1993) (73)
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. (2013) (73)
Under-reporting of harm in clinical trials. (2016) (72)
Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia (2012) (72)
Goals of palliative cancer therapy. (1993) (71)
Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? (2012) (71)
Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis (2014) (70)
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. (2019) (69)
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. (1980) (69)
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. (1999) (68)
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues (2013) (68)
Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib (2012) (67)
Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study (2005) (66)
Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. (2001) (66)
Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. (2014) (66)
Failures in Phase III: Causes and Consequences (2015) (65)
Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. (1998) (64)
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer (2008) (63)
Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs (2001) (62)
Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. (2018) (62)
The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. (2002) (62)
Vitamin A and the radiation response of experimental tumors: an immune-mediated effect. (1972) (62)
The Effects of Chemotherapy on Cognitive Function in a Mouse Model: A Prospective Study (2012) (62)
Relevance of randomised controlled trials in oncology. (2016) (62)
Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. (2007) (61)
Lysosomes, lysosomal enzymes, and cancer. (1993) (61)
The age sensitivity of epithelial cells of mouse small intestine. (1970) (60)
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. (2011) (60)
Physical exercise prevents suppression of hippocampal neurogenesis and reduces cognitive impairment in chemotherapy-treated rats (2014) (60)
Chemotherapy for adenocystic carcinoma (1980) (60)
Tumor growth and cell kinetics in chronically hypoxic animals. (1970) (60)
Cytostatic potential of novel agents that inhibit the regulation of intracellular pH (2002) (60)
Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. (1989) (60)
The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation. (2015) (59)
"PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer. (2002) (59)
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. (2011) (58)
Treating the patient, not just the cancer. (1987) (57)
The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. (2009) (57)
Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going? (2008) (56)
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors (2009) (56)
Effects of agents which inhibit the regulation of intracellular pH on murine solid tumours. (1992) (56)
Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit? (2016) (56)
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. (2009) (55)
Activity of the hypoxia‐activated pro‐drug TH‐302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy (2014) (54)
Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse model (2011) (54)
Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reporting. (2004) (53)
Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cancer cell line. (1986) (53)
Factors that influence the penetration of methotrexate through solid tissue (2001) (53)
Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. (2014) (53)
Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts (2009) (53)
Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. (2016) (52)
A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). (2004) (51)
Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy (2015) (51)
Adjuvant chemotherapy for breast cancer: discordance between physicians' perception of benefit and the results of clinical trials. (1994) (50)
Company stock prices before and after public announcements related to oncology drugs. (2011) (50)
Sorafenib for Metastatic Renal Cancer: The Princess Margaret Experience (2008) (49)
Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study. (2010) (49)
Effects of long‐term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer (2017) (49)
Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors (2013) (48)
Validation of a predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. (2009) (48)
The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer (2009) (48)
Analyzing the same data in two ways: a demonstration model to illustrate the reporting and misreporting of clinical trials. (1989) (48)
Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? (2006) (48)
Criteria of tumor response used in clinical trials of chemotherapy. (1985) (48)
A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. (2002) (48)
The influence of expression of P‐glycoprotein on the penetration of anticancer drugs through multicellular layers (2000) (47)
Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them (2015) (47)
The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis. (2019) (47)
Experimental chemotherapy and concepts related to the cell cycle. (1986) (46)
On the existence of a G 0 -phase in the cell cycle. (1970) (46)
Reduction of Intracellular pH as a Strategy to Enhance the pH-Dependent Cytotoxic Effects of Melphalan for Human Breast Cancer Cells (2005) (46)
Concurrent cyclophosphamide, methotrexate, and 5‐fluorouracil chemotherapy and radiotherapy for breast carcinoma (2002) (45)
Quality of cancer care. (2004) (45)
The paradox of precision medicine (2018) (45)
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. (2015) (45)
A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin (2014) (44)
Long‐term impact of androgen‐deprivation therapy on physical function and quality of life (2015) (44)
Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. (2006) (43)
Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation—An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302 (2015) (42)
A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer (2019) (42)
Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy. (1994) (42)
Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results. (1983) (41)
Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. (2003) (41)
Bias in reporting of randomised clinical trials in oncology. (2016) (41)
The translational research chain: is it delivering the goods? (2001) (41)
How American oncologists treat breast cancer: an assessment of the influence of clinical trials. (1991) (41)
Management of decreased bone mineral density in men starting androgen‐deprivation therapy for prostate cancer (2009) (41)
Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study. (2015) (40)
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma (2007) (40)
Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost (1999) (40)
Neurobiological Mechanisms of Chemotherapy-induced Cognitive Impairment in a Transgenic Model of Breast Cancer (2018) (40)
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. (1998) (40)
Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. (2000) (39)
Use and misuse of common terminology criteria for adverse events in cancer clinical trials (2016) (39)
Quality of life and understanding of disease status among cancer patients of different ethnic origin (2003) (39)
Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors (2015) (39)
Screening trials are even more difficult than we thought they were. (2002) (38)
Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer (2013) (38)
Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy (2018) (37)
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. (2012) (36)
A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. (1993) (36)
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. (2013) (36)
Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D (2013) (36)
Trials in palliative treatment--have the goal posts been moved? (2008) (36)
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin. (1980) (36)
The response of viable tumor cords to a single dose of radiation. (1973) (34)
Flow cytometric calibration of intracellular pH measurements in viable cells using mixtures of weak acids and bases. (1996) (34)
Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. (2009) (34)
Combination chemotherapy used prior to radiation therapy for locally advanced squamous cell carcinoma of the head and neck. (1982) (34)
Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel. (2012) (34)
Memory loss in chemotherapy-treated rats is exacerbated in high-interference conditions and related to suppression of hippocampal neurogenesis (2015) (33)
Adjuvant Therapy for Node-Negative Breast Cancer (1989) (33)
Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. (2011) (33)
The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts (2015) (32)
Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. (2003) (32)
Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity (2017) (32)
Genitourinary tumors, non-prostate (2012) (31)
Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap. (2020) (31)
Use of Molecular Biomarkers to Quantify the Spatial Distribution of Effects of Anticancer Drugs in Solid Tumors (2013) (31)
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. (2004) (31)
Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. (2002) (30)
Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience. (1998) (30)
Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function (2007) (30)
Is there a role for chemotherapy in prostate cancer? (2004) (30)
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium (2013) (29)
Evaluation of treatment benefit: randomized controlled trials and population-based observational research. (2013) (28)
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). (2019) (28)
Eradication of a disease: how we cured symptomless prostate cancer (2002) (28)
Intra-individual Variability in Women with Breast Cancer (2014) (28)
Antitumor activity of nigericin and 5-(N-ethyl-N-isopropyl)amiloride: an approach to therapy based on cellular acidification and the inhibition of regulation of intracellular pH. (1994) (28)
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. (2014) (27)
Priorities for cancer research in low- and middle-income countries: a global perspective (2022) (27)
Informative censoring — a neglected cause of bias in oncology trials (2020) (27)
Xenografts of human bladder cancer in immune-deprived mice. (1982) (27)
Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. (2010) (26)
Postoperative radiotherapy for breast cancer: growing evidence for an impact on survival. (2004) (26)
Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). (2013) (26)
Biology of Tumor Growth (1983) (26)
Pretreatment Differences in Intraindividual Variability in Reaction Time between Women Diagnosed with Breast Cancer and Healthy Controls (2016) (26)
Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine (2014) (26)
Failure of short‐course multiple drug chemotherapy to benefit patients with recurrent or metastatic head and neck cancer (1982) (25)
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer (2008) (25)
Some problems related to the design and analysis of clinical trials. (1992) (25)
Comparison of growth of human bladder cancer in tissue culture or as xenografts with clinical and pathological characteristics. (1984) (25)
Systemic treatment for prostate cancer. (1998) (24)
Malignant properties of sublines selected from a human bladder cancer cell line that contains an activated c-Ha-ras oncogene. (1988) (24)
Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. (2015) (24)
The association between radiographic response and overall survival in men with metastatic castration‐resistant prostate cancer receiving chemotherapy (2011) (24)
Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. (2006) (24)
Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours. (1993) (24)
A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone. (2016) (23)
Honorary and ghost authorship in reports of randomised clinical trials in oncology. (2016) (23)
Chemotherapy for patients with hormone-refractory prostate cancer. (2004) (23)
Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept (2013) (23)
Effect of the Selective Estrogen Receptor Modulator Arzoxifene on Repopulation of Hormone-Responsive Breast Cancer Xenografts between Courses of Chemotherapy (2005) (23)
Influence of cell concentration in limiting the therapeutic benefit of P‐glycoprotein reversal agents (1999) (23)
Broadening horizons in medical management of prostate cancer (2011) (22)
Eradication of a disease: how we cured asymptomatic prostate cancer (2000) (22)
Variation of pO2 in the growth medium of spheroids: interaction with glucose to influence spheroid growth and necrosis. (1986) (22)
Effects of food on bioavailability of lapatinib: useful data, wrong conclusion. (2009) (22)
Oxygen distribution in tumours: influence on cell proliferation and implications for tumour therapy. (1976) (22)
Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation. (2004) (22)
A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer. (2011) (21)
How American oncologists treat breast cancer: An assessment of the influence of clinical trials (1991) (21)
Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients (2012) (21)
Response criteria phase II/phase III invasive bladder cancer. (1986) (21)
Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone? (2002) (21)
Effectiveness of Specialized Palliative Care (2008) (21)
Cancer: Resistance through repopulation (2014) (21)
Quality of life measurement in breast cancer patients. (1985) (21)
Chemotherapy for metastatic transitional carcinoma of the urinary tract: A prospective trial of methotrexate, adriamycin, and cyclophosphamide (MAC) with cis‐platinum for failure (1983) (21)
When is a cancer treatment worthwhile? (1990) (21)
Influence of reduced concentration of L-glutamine on growth and viability of cells in monolayer, in spheroids, and in experimental tumours. (1986) (20)
Mechanisms of interaction between radiation and drugs with potential for improvements in therapy. (1988) (20)
Failure of 2-deoxy-D-glucose and 5-thio-D-glucose to kill hypoxic cells of two murine tumors. (1983) (20)
Recursive partitioning analysis of prognostic factors for survival in patients with advanced cancer. (2009) (20)
Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice. (2014) (19)
Levels of sex hormones have limited effect on cognition in older men with or without prostate cancer. (2010) (19)
Chemotherapy dose escalation: case unproven. (1997) (19)
Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. (2003) (19)
A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer. (2001) (19)
The recruitment of patients into clinical trials. (1995) (19)
Environmental enrichment protects against cognitive impairment following chemotherapy in an animal model. (2016) (18)
Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer (2005) (18)
Experimental models of bladder cancer: a critical review. (1986) (18)
Potential for therapeutic gain from combined-modality treatment. (1992) (18)
Cluster-randomized trial of early palliative care for patients with metastatic cancer. (2012) (18)
Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: Pilot study (2003) (17)
Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit? (2017) (17)
Critical evaluation of disease stabilization as a measure of activity of systemic therapy: lessons from trials with arms in which patients do not receive active treatment. (2014) (17)
Neoadjuvant chemotherapy in head and neck cancer: no way to preserve a larynx. (1992) (16)
The radiation response of human bladder cancer assessed in vitro or as xenografts in immune-deprived mice. (1984) (16)
Human Tumor Cell Kinetics (1970) (16)
Unconventional therapies for cancer: a refuge from the rules of evidence? (1998) (16)
The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. (2014) (16)
Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets (2020) (16)
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? (2021) (15)
Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract. (1983) (15)
How valid are claims for synergy in published clinical studies? (2012) (15)
pH dependent cytotoxicity of N-dodecylimidazole: a compound that acquires detergent properties under acidic conditions. (1993) (15)
Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues? (1990) (15)
Commentary on "cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group Trial 8949". (2000) (15)
Comparison of Eligibility Criteria Between Protocols, Registries, and Publications of Cancer Clinical Trials. (2016) (15)
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. (2021) (15)
Global drug development in cancer: a cross-sectional study of clinical trial registries. (2010) (14)
Toward Value-Based Pricing to Boost Cancer Research and Innovation. (2016) (14)
Doctor's dilemma: incorporating tumor markers into clinical decision-making. (2002) (14)
Influence of censoring on conclusions of trials for women with metastatic breast cancer. (2015) (14)
Pharmacokinetic studies of amiloride and its analogs using reversed-phase high-performance liquid chromatography. (1996) (14)
Cognitive function and fatigue in colorectal cancer (CRC) patients: Baseline assessments prior to chemotherapy. (2016) (14)
Words of wisdom. Re: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. (2014) (13)
A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC) (2007) (13)
10-year analysis of the ATAC trial: wrong conclusion? (2011) (13)
Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience. (2014) (13)
Failure of 5-day vinblastine infusion in the treatment of patients with advanced refractory breast cancer. (1982) (13)
Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. (2006) (13)
The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research. (2021) (13)
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead. (2022) (13)
Improving Access to Immunotherapy in Low and Middle-Income Countries (2022) (13)
Chemotherapy for head and neck cancer. (1984) (13)
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. (2014) (13)
Management of breast and prostate cancer: how does quality of life enter the equation? (1990) (12)
Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice. (2014) (12)
The transition from phase II to phase III studies. (2009) (12)
How Low Can You Go? PD-L1 Expression as a Biomarker in Trials of Cancer Immunotherapy. (2021) (12)
Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. (2012) (12)
Use and misuse of waterfall plots. (2014) (12)
Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. (2011) (12)
Improving Treatment for Advanced Prostate Cancer. (2019) (12)
Phase II study of cytarabine in men with docetaxel‐refractory, castration‐resistant prostate cancer with evaluation of TMPRSS2‐ERG and SPINK1 as serum biomarkers (2012) (12)
Benefits of Adjuvant Chemotherapy for Bladder Cancer. (2015) (12)
Molecular screening to select therapy for advanced cancer? (2019) (11)
Clinical relevance of breast cancer biology. (1994) (11)
The effect of heat on Na+/H+ antiport function and survival in mammalian cells. (1996) (11)
Toxicity of 5-fluorouracil for aerobic and hypoxic cells in two murine tumours (2004) (11)
Malignant pheochromocytoma of the urinary bladder. (2007) (11)
The changing face of hormonal therapy for prostate cancer. (2008) (11)
The prognostic effect of lipids on early-stage breast cancer (BC) outcome (2005) (11)
Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy. (2016) (11)
Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC) (2007) (11)
Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer (2008) (11)
Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC). (2015) (11)
DES versus tamoxifen in advanced breast cancer. (1981) (11)
Molecular screening to select therapy for advanced cancer? (2019) (11)
The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer (2007) (10)
Removing the primary tumor after the cancer has spread. (2001) (10)
Endpoints of clinical trials in invasive bladder cancer. (1990) (10)
Ethics in oncology: consulting for the investment industry. (2007) (10)
Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer. (2020) (10)
Should screen-detected breast cancers be managed differently? (2005) (10)
The effects of vasodilating drugs on pH in tumors. (1999) (9)
Clinical Trials in Genitourinary Oncology: What Have They Achieved? (1989) (9)
Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens. (2016) (9)
Influence of measurement error on response rates. (1985) (9)
Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer. (1992) (9)
Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology (2015) 26(8) (1589–1604), (S0923753419318691), (10.1093/annonc/mdv257)) (2019) (9)
Use of a physician-directed questionnaire to define a consensus about management of breast cancer: implications for assessing costs and benefits of treatment. (1992) (8)
A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC) (2007) (8)
Overview of Canadian trials in hormonally resistant prostate cancer. (1996) (8)
Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. (2019) (8)
Toxicity of aziridinylbenzoquinone for aerobic and hypoxic cells of a transplanted mouse mammary tumor and interaction of the drug with radiation and adriamycin. (1983) (8)
Response to systemic therapy in non-clear cell renal cell carcinomas: A systematic review and meta-analysis. (2014) (8)
An attempt at selective chemotherapy of hypoxic cells: triethylenemelamine and irradiation of a C3H mouse mammary tumour. (1972) (8)
Limits to Precision Cancer Medicine. (2017) (8)
Interleukin-2 for metastatic melanoma: treating polyuria with insulin? (1990) (8)
Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC) (2007) (8)
Treating the patient, not just the cancer. (1987) (8)
Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer (2015) (8)
Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer (2018) (8)
Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function. (2006) (7)
The basic science of oncology. 5th edition. (2013) (7)
Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC). (2018) (7)
Collaborative clinical trials: quality or quantity? (2001) (7)
Axillary node dissection in breast cancer (1992) (7)
The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study. (2013) (7)
Growth and characterization of multicellular tumor spheroids of human bladder carcinoma origin (1986) (7)
The potential of lactate and succinate to kill nutrient deprived tumor cells by intracellular acidification. (1991) (7)
Methods of immunosuppression for study of growth and lung colony formation by human tumor cells in mice. (1986) (7)
New perspectives in combined radiotherapy and chemotherapy treatment. (1994) (7)
Misonidazole increases the toxicity of BCNU for hypoxic cells. (1982) (7)
Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy (2016) (7)
The current status of adjuvant chemotherapy for bladder cancer. (1990) (6)
Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials? (2019) (6)
Global drug development in cancer: A cross-sectional study of clinical trial registries. (2009) (6)
Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. (2019) (6)
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer (2012) (6)
ASCO core values. (2006) (6)
Abiraterone in Metastatic Prostate Cancer. (2017) (6)
Can Oncologists Predict the Efficacy of Treatments in Randomized Trials? (2020) (6)
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. (2017) (6)
OP5. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone resistant prostate cancer based on a Canadian randomised trial with palliative endpoints (1997) (6)
Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor (2013) (6)
Prostate cancer: 11. Alternative approaches and the future of treatment. (1999) (5)
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? (2012) (5)
Updating Reports of Phase 3 Clinical Trials for Cancer. (2021) (5)
Cognitive function, fatigue and menopausal symptoms in women following adjuvant chemotherapy for breast cancer: One and two year follow-up of a prospective controlled study. (2004) (5)
Low-dose abiraterone (abi) with food in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre experience. (2014) (5)
A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer. (2001) (5)
Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial. (2010) (5)
AContemporary Prognostic Nomogram for Menwith Hormone-Refractory Metastatic Prostate Cancer : ATAX 327 StudyAnalysis (2007) (5)
Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access (2022) (5)
Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer (2017) (5)
A critique of the fragility index - Authors' reply. (2019) (5)
Failure of 5-day vinblastine infusion in the treatment of patients with renal cell carcinoma. (1985) (5)
Limited penetration of anticancer drugs to cells in solid tumors: A neglected and modifiable cause of drug resistance (2005) (5)
Value-Added Decisions in Oncology. (2019) (5)
The five Rs of chemotherapy. (2016) (5)
Biology and tumor growth. (1983) (5)
Introduction to discussion (1995) (5)
Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. (2011) (5)
Quality of life and satisfaction with care in caregivers of patients with advanced cancer: Results from a trial of early palliative care. (2015) (5)
Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. (2012) (5)
A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma. (2016) (4)
A fatal case of Pneumocystis jirovecii pneumonia in a breast cancer patient receiving weekly paclitaxel and trastuzumab (2012) (4)
Treatment of lung cancer. (2009) (4)
From evidence-based medicine to clinical practice: not always straightforward (2003) (4)
Have Investigators Forgotten How to Write? (2021) (4)
Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). (2011) (4)
Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC). (2013) (4)
Myelosuppression and infective complications (2001) (4)
Abstract A51: Chemotherapy rescues hypoxic tumor cells and induces reoxygenation and repopulation - an effect that is inhibited by the hypoxia-activated pro-drug TH-302 (2015) (4)
CELL KINETICS—WHERE TO NOW? * (1980) (4)
Can modelling of PSA dynamics accelerate drug development for prostate cancer? (2017) (4)
Do contemporary randomized controlled trials meet ESMO thresholds for clinically meaningful benefit (2016) (4)
The effect of the drug lonidamine on Chinese hamster ovary cells in vitro and on experimental tumors. (1984) (4)
Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study? (2009) (4)
Purchasing silence. (2018) (4)
Mathematics in the realm of lapatinib: 500 + 500 = 1,500? (2008) (4)
The European Union and personalised cancer medicine. (2021) (4)
Flawed trials for cancer. (2020) (4)
7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC) (2009) (4)
Do women with primary breast cancer who experience chemotherapy-induced menopause have worse symptoms than those due to natural menopause? (2005) (3)
Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC). (2013) (3)
Low-Fat Abiraterone Food Effect Is of Great Consequence. (2018) (3)
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving fi rst-line chemotherapy : data from two randomized phase III trials † (2015) (3)
839PPHASE II STUDY OF INDIVIDUALIZED SUNITINIB AS FIRST-LINE THERAPY FOR METASTATIC CLEAR CELL RENAL CELL CANCER (MRCC). (2014) (3)
Prostate cancer: Androgen deprivation therapy and bone loss (2009) (3)
Retreatment of men with metastatic castrate‐resistant prostate cancer with abiraterone (2014) (3)
Lack of cognitive impairment in long-term survivors of colorectal cancer (2022) (3)
Analysis of trials using chemotherapy for metastatic bladder cancer. (1988) (3)
Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer. (2014) (3)
Should Basket Trials Be Pathways to Drug Registration for Biomarker-Defined Subgroups of Advanced Cancers? (2021) (3)
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study. (2010) (3)
Comparison of results between the first and updated reports of phase III clinical trials (RCTs). (2014) (3)
Delivering Affordable Cancer Care in High-income Countries: a Lancet Oncology Commission (2011) (3)
Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment. (2014) (3)
Studying the Effectiveness of Palliative Care. Authors' reply (2008) (3)
Prospective Study Evaluating the Impact of Tissue Conﬁrmation of Metastatic Disease in Patients With Breast Cancer (2012) (3)
Breast cancer: Tamoxifen—when more might be better (2013) (3)
Talking to a patient. (2005) (3)
A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy. (2014) (3)
How valid are claims for synergy in published clinical studies? (2012) (3)
Possible role of cell kinetics in prediction of the response to cancer therapy. (1971) (2)
1973 Epidermal growth factor receptor (EGFR) over-expression and outcomes in early breast cancer: A systematic review and meta-analysis (2015) (2)
Cis-platinum and hormones in cancer of prostate. (1980) (2)
Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma. (2022) (2)
The impact of baseline serum testosterone and duration of first-line androgen deprivation therapy on the efficacy of docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). (2014) (2)
Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment. (2018) (2)
Abstract P2-05-12: Effects of de-escalated bisphosphonate therapy on bone turnover or metastasis markers and their correlation with risk of skeletal related events – A biomarker analysis in conjunction with the REFORM study. (2012) (2)
Drug interactions in ambulatory cancer patients receiving cancer-directed therapy. (2006) (2)
Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience. (2014) (2)
Is physical function affected by androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer? (2006) (2)
Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (2)
Perioperative Chemotherapy for Muscle-Invasive Bladder Cancer (2014) (2)
Will increases in chemotherapy dose intensity improve outcome of patients with common malignancies? (1995) (2)
1869 UTILIZATION AND IMPACT OF PERI-OPERATIVE CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER: A POPULATION-BASED OUTCOMES STUDY (2013) (2)
Trends in the quality of abstracts of articles describing randomized controlled cancer trials (RCTs) from 1975–2004 (2007) (2)
From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC). (2013) (2)
Neoadjuvant (NACT) and Adjuvant Chemotherapy (ACT) for Muscle-Invasive Bladder Cancer: A Population-Based Outcomes Study (2012) (2)
Slogans and donor pages of cancer centres: do they convey discordant messages? (2018) (2)
Cognitive impairment in adolescent and young adult cancer patients: Pre‐treatment findings of a longitudinal study (2022) (2)
Dose escalation of gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer (2010) (2)
Physical exercise prevents suppression of hippocampal neurogenesis and reduces cognitive impairment in chemotherapy-treated rats (2013) (2)
AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium. (2007) (2)
Phase II Multicenter Study of Epirubicin for Hormone‐resistant Prostatic Cancer with Measurable Soft Tissue Disease (1993) (2)
Avoiding the hazards of misinterpreting treatment effects. (2019) (2)
Effect of multifocality and multicentricity on outcome in early breast cancer: A systematic review and meta-analysis. (2014) (2)
Does the hurria/CARG tool or VES-13 predict grade 3 + toxicities in men undergoing chemotherapy for metastatic prostate cancer? (2013) (2)
Adoption of neoadjuvant (NACT) and adjuvant chemotherapy (ACT) for bladder cancer: A population-based study. (2011) (2)
Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study. (2006) (2)
Problems Associated with the Assessment of Patients with Metastatic Breast Cancer: Can Past Experience Teach us to do Better Clinical Trials? (1987) (2)
Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study. (2012) (2)
Nonrandomized clinical trials of cancer chemotherapy: phase II or III? (1988) (2)
Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medication: a pilot project at a Canadian cancer center. (2013) (2)
CRITICAL ISSU-ES IN TUMOR MICROCIRCULATION, ANGIOGENESIS AND METASTASIS: BIOLOGICAL SIGNIFICANCE AND CLINICAL RELEVANCE (1993) (2)
Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold? (2021) (2)
Androgen deprivation therapy (ADT) and physical function in men with nonmetastatic prostate cancer (2008) (2)
Disclosure-in the blink of an eye. (2019) (1)
Testosterone-guided schedule of androgen deprivation therapy (ADT) as an alternative to a fixed schedule in management of prostate cancer. (2015) (1)
Impact of 36 months of androgen-deprivation therapy (ADT) on physical function and quality of life (QOL) in men with nonmetastatic prostate cancer. (2012) (1)
Quality control in chemotherapy. (1991) (1)
P30 36 WP – INTRACELLULAR pH REGULATION AND HEAT SENSITIVITY in vitro (1991) (1)
Impact of androgen deprivation therapy (ADT) on bone mineral density (BMD) over 3 years in men with nonmetastatic prostate cancer. (2012) (1)
Clinical research in oncology: in memory of Professor Gordon McVie (2022) (1)
Rationale and evidence for the use of sunitnib to treat patients with malignant paraganglioma/pheochromocytoma (MPP) (2008) (1)
Cautionary Tails. (2020) (1)
Endpoints of clinical trials for muscle-invasive bladder cancer. (1990) (1)
117INSHOULD PERSONALISED MEDICINE BE FUNDED IN COUNTRIES WITH LIMITED RESOURCES? (2014) (1)
Spin and bias: the tip of the iceberg. (2013) (1)
Tumour response to chemotherapy in animals that have been treated with the same drugs prior to tumour implantation: a model for studying host effects on apparent drug resistance. (1988) (1)
Oncology in 2050 - A Retrospective? (2020) (1)
Rules for the conduct of clinical trials need revision, but "good clinical practice" requires much more. (2022) (1)
Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians. (2017) (1)
Are prostate cancer clinical trial enrollment criteria and endpoints appropriate? (2006) (1)
Biological basis of combined therapy (1994) (1)
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel (2020) (1)
A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer (2017) (1)
Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib (2012) (1)
acompound that acquires detergent properties underacidic conditions (1993) (1)
Disclosure-in the blink of an eye. (2019) (1)
Cell proliferation, drug distribution and therapeutic effects in relation to the vascular system of solid tumours (2022) (1)
Assessment of study design in clinical trials for bladder cancer. (1992) (1)
Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC) (2016) (1)
Harms of Intermittent vs Continuous Androgen-Deprivation Therapy for Prostate Cancer. (2016) (1)
Abstract A54: Pantoprazole enhances the activity of docetaxel chemotherapy for solid tumors by inhibition of autophagy (2015) (1)
Do special access programs facilitate off-label prescribing? The experience of enzalutamide in prostate cancer. (2014) (1)
The balance between benefits and harms of molecular targeted agents. (2011) (1)
Study of testosterone‐guided androgen deprivation therapy in management of prostate cancer (2016) (1)
Statistical power of negative randomized clinical trials (RCTs) presented at the American Society of Clinical Oncology (ASCO) Annual Meetings (2007) (1)
Abstract 395: Effect of pantoprazole to enhance activity of docetaxel against human tumor xenografts by inhibiting autophagy (2015) (1)
Impact of 12 months of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC): A matched cohort study. (2010) (1)
Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. (2004) (1)
Evaluation of the probability of spontaneous transfer of drug resistance between cells in culture (1991) (1)
A prospective study examining PROs and other geriatric outcomes in older adults with prostate cancer undergoing chemotherapy. (2013) (1)
Alternative views on alternative therapies (1999) (1)
Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer? (2023) (1)
Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trials (2021) (1)
Long-term effects of conservation therapy for muscle invasive bladder carcinoma. (2004) (1)
The reporting of trials of adjuvant therapy for breast cancer. (1990) (1)
Comment on Angulo et al.: "A Man's got to know his limitations". (1995) (1)
Choosing a better end point for trials of bone-protective agents. (2015) (0)
Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology. (2011) (0)
Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated on (2016) (0)
Declines in physical function from androgen deprivation therapy (ADT) in men with nonmetastatic prostate cancer: A matched cohort study. (2009) (0)
Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs). (2010) (0)
Reduction of Intracellular pHas a Strategy to Enhance the pH-Dependent Cytotoxic Effects ofMelphalan for Human Breast Cancer Cells (2005) (0)
Issue information (2015) (0)
S23 06 WA – PROSPECTS FOR DRUGS EXPLOITING LOWER TUMOR pH (1991) (0)
Impact of androgen deprivation therapy (ADT) on quality of life (QL), cognitive and physical function of patients with non-metastatic prostate cancer (PC) (2005) (0)
Socioeconomic Factors, Urological Epidemiology and Practice Patterns Re: Delivering Affordable Cancer Care in High-Income Countries (2011) (0)
2589 Adjuvant radiation therapy after radical nephrectomy in patients with localized renal cell carcinoma: a systematic review and meta-analysis (2015) (0)
Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC). (2015) (0)
The distribution of anti-cancer drugs in relation to blood vessels in solid tumors (2004) (0)
Original article Long-term outcome of radiation-based conservation therapy for invasive bladder cancer (2007) (0)
Quality assessment of clinical trials in bladder cancer. (1988) (0)
In reply [12] (2007) (0)
Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results. (1983) (0)
1386O_PRRISK OF INCREMENTAL TOXICITIES AND ASSOCIATED COSTS OF NEW ANTICANCER DRUGS: A META-ANALYSIS (2014) (0)
Drug/radiation interactions (1990) (0)
The influence of the proton pump inhibitor pantoprazole on the distribution of doxorubicin in solid tumors with and without expression of P-glycoprotein (2008) (0)
Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology. (2011) (0)
Sorafenib for the treatment of metastatic renal cancer (MRC) in the real world: The Princess Margaret Hospital (PMH) experience (2007) (0)
Can we afford the future: effectiveness or cost-effectiveness as the criterion for introducing new therapies for breast cancer? (2008) (0)
Abstract 560: The use of molecular biomarkers to quantify drug distribution in solid tumors (2011) (0)
Hormonal Anticancer Treatment in the Senior Cancer Patient (2010) (0)
A National Cancer Institute of Canada Clinical Trials Group phase II study of eniluracil ( 776 C 85 ) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer (2005) (0)
Session IV—AbstractAdriamycin: Effects on aerobic and hypoxic cells of the 16C tumor and interaction with misonidazole (1982) (0)
Erratum (2015) (0)
Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status (2004) (0)
Impact of 24 months of androgen deprivation therapy (ADT) on physical function in men with nonmetastatic prostate cancer. (2011) (0)
Abstract 3829A: Pantoprazole enhances the activity of chemotherapy for solid tumors by inhibition of autophagy. (2013) (0)
Abstract 5247: Use of two markers of hypoxia to study migration, re-oxygenation and repopulation of originally hypoxic cells in MCF-7 tumor xenografts following chemotherapy (2012) (0)
Cognitive F unction i n B reast C ancer P atients R eceiving Adjuvant C hemotherapy (2000) (0)
Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed? (2022) (0)
Neoadjuvant gemcitabine-cisplatin (GC) for muscle-invasive bladder cancer (MIBC): Does midway CT staging predict for pathologic complete response (pCR)? (2014) (0)
Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE). (2014) (0)
Chemotherapy in Advanced Nasopharyngeal Cancer (2017) (0)
Extended lymphadenectomy and adjuvant chemotherapy in muscle-invasive bladder cancer treated by radical cystectomy. (2012) (0)
Summary of discussion (1995) (0)
Abstract 3801A: Reoxygenation and repopulation of hypoxic cells in a solid tumor after chemotherapy: a cause of treatment failure. (2013) (0)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (0)
Studying the Effectiveness of Palliative Care—Reply (2008) (0)
Decision letter: Topography of cancer-associated immune cells in human solid tumors (2018) (0)
Bias in reporting of endpoints of efficacy and toxicity in randomized clinical trials (RCTs) for women with breast cancer (BC). (2012) (0)
The effect of ADT on objective cognitive performance and self-reported cognitive functionin men with prostate cancer. (2010) (0)
Knowing your tumour? (2020) (0)
Evolution of Clinical Trial Design in Early Drug Development: The Use of Expansion Cohorts (ECS) in Phase I Cancer Trials (PITS) (2012) (0)
Abiraterone in Metastatic Prostate Cancer. (2017) (0)
Delivery of peri-operative chemotherapy for muscle-invasive bladder cancer (MIBC) in routine clinical practice: Does regimen and timing matter? (2014) (0)
P39 01 TP – USE OF GLYCOLYSIS-DEFICIENT CELLS TO EXAMINE THE RELATIONSHIP BETWEEN LACTATE PRODUCTION AND TUMOUR ACIDITY (1991) (0)
The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force (2022) (0)
786PTHE IMPACT OF THE DERIVED NEUTROPHIL TO LYMPHOCYTE RATIO AND DURATION OF INITIAL ANDROGEN DEPRIVATION THERAPY (ADT) ON SURVIVAL OF MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING FIRST-LINE CHEMOTHERAPY: DATA FROM TWO RANDOMIZED PHASE III TRIALS. (2014) (0)
Dr. Richard (Dick) Hill 1942–2021 (2021) (0)
More pharmaceutical company influence? (1998) (0)
Quality oflife measurementinbreast cancerpatients (1985) (0)
Palliative treatments for metastatic cancer, and use of quality of life endpoints to assess them (1999) (0)
Preface (0)
PERSONAL PSA SCREENING AND TREATMENT CHOICES FOR LOCALIZED PROSTATE CANCER AMONG EXPERT PHYSICIANS: PD07‐07 (2017) (0)
Cellular and molecular biology of neoplasia : proceedings of a symposium held at Honey Harbor, Ontario, Canada, October 2-6, 1983 (1984) (0)
Absolute benefits of experimental medical therapies in phase III randomized clinical trials (RCTs) in breast and colorectal cancer. (2016) (0)
Cancer biology: Editorial overview (1990) (0)
Cognitive F unction, F atigue, a nd M enopausal S ymptoms i n Women R eceiving A djuvant C hemotherapy f or B reast C ancer (2003) (0)
Hormone-Resistant Prostate Cancer: New Therapies Needed (2007) (0)
Abstract P6-09-02: Pre-treatment cognitive function (CF) in women with locally advanced breast cancer (LABC) and in healthy controls. (2012) (0)
Cytotoxic effect of hypoxia plus low ph and of agents that interfere with the regulation of intracellular ph (1986) (0)
Ronald N. Buick 1948–1996 (1996) (0)
9 New developments in the systemic treatment of advanced prostate cancer (2011) (0)
Is the use of progression-free survival a valid endpoint for trials of drug combinations in oncology? (2022) (0)
Relationship between sex hormones and cognition in men with and without prostate cancer (2005) (0)
Impact of 36 months of androgen-deprivation therapy (ADT) on physical function and quality of life (QOL) in men with nonmetastatic prostate cancer. (2012) (0)
Adjuvant radiation or systemic therapy for renal cell carcinoma: A brief review. (1995) (0)
Effectiveness of Specialized Palliative Care : A Correction (2008) (0)
Analysis of survival by palliative response in patients with symptomatic hormone refractory prostate cancer (1998) (0)
Alternative approaches and the future of treatment (2002) (0)
Radiographic progression-free survival in the ACIS trial for prostate cancer. (2022) (0)
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer (2023) (0)
Absolute risk and cost of management of toxicities of newly approved anticancer drugs: A meta-analysis. (2014) (0)
Gastrointestinal tumours/Genito-urinary tumours (2005) (0)
Do women who self-report cognitive symptoms after breast cancer treatment have more cognitive impairment than those who do not report symptoms? A mechanistic cohort study with functional brain MRI. (2016) (0)
The influence of extracellular matrix (ECM) on penetration of anticancer drugs through solid tumor tissue (2004) (0)
Abstracts from the 33rd Annual Scientific Meeting of the Canadian Geriatrics Society Toronto, April 2013 (2013) (0)
Extended lymphadenectomy and adjuvant chemotherapy in muscle-invasive bladder cancer treated by radical cystectomy. (2012) (0)
Dose Intensity in Chemotherapy (1985) (0)
55 Drug resistance in metastatic prostate cancer (2009) (0)
Abstract 5246: Use of γH2aX and other biomarkers to quantify distribution of drug activity in solid tumors (2012) (0)
Keynote lecture: New developments in the systemic treatment of advanced prostate cancer (2011) (0)
106INIF AND WHEN TO START SYSTEMIC THERAPY AS PALLIATION FOR PEOPLE WITH ADVANCED CANCER. (2014) (0)
BEST VS AFFORDABLE TREATMENT OPTIONS IN PROSTATE CANCER (2018) (0)
Companion Diagnostics to Identify Biomarkers of Response to Anticancer Drugs Targeting the Proteome. (2019) (0)
PROSPECTS FOR DRUGS EXPLOITING LOWER TUMOR pH (1992) (0)
Cancer Therapy : Preclinical Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin : A Potential Strategy to Improve the Therapy of Solid Tumors (2014) (0)
667 Cancer clinical trials - the key to improving outcome (2003) (0)
BEST VERSUS AFFORDALE TREATMENT OPTIONS IN PROSTATE CANCER (2019) (0)
Treatment of octogenarians with castration-resistant prostatecancer with abiraterone and docetaxel (2013) (0)
Cell proliferation in relation to vascularity and oxygenation. Abstr. (1967) (0)
Study design in the age of molecular biology (2006) (0)
158 INVITED Cross-over in Clinical Trials – the Clinician's Perspective (2011) (0)
Carbonylcyanide-3-Chlorophenylhydrazone A Prototype Agent for the Selective Killing of Cells in Acidic Regions of Solid Tumours (1989) (0)
Abstract C25: A phase I study evaluating the proton pump inhibitor pantoprazole (PTP) in combination with doxorubicin (DOX) for advanced cancer patients (pts). (2011) (0)
Systemic treatment for elderly women with breast cancer: tradeoffs between duration and quality of survival (2006) (0)
The Distribution of theAnticancer Drug Doxorubicin in Relation to BloodVessels in SolidTumors (2005) (0)
Organisation for Oncology and Translational Research Newsletter (2015) (0)
PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
Cancer Clinical Trials in the Tropical Area (2015) (0)
A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer. (2011) (0)
Reply to J. Zhu et al. (2013) (0)
Delivery of meaningful cancer care: Evaluating benefit and cost of cancer therapies using ASCO and ESMO frameworks. (2017) (0)
Synergy made simple: What does it mean and how valid are claims for synergy between antitumor agents? (2010) (0)
Carbonylcyanide-3-chlorophenylhydrazone Killing Cells in Acidic Regions of Solid Tumors : Effects of Reduction of Intracellular pH as a Possible Mechanism for Updated (2006) (0)
The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts (2015) (0)
The effect of adriamycin (adr) on a human bladder cell line (mgh-u1) grown as a monolayer, as spheroids and in immune-deprived mice. Abstr. (1982) (0)
Use of the Prostate Cancer-specific Quality of Life Instrument (PROSQOLI) in clinical practice. (2009) (0)
Autophagy is a mechanism of resistance to anticancer drugs that can be targeted to improve the effectiveness of cancer therapy (2015) (0)
Responsibility in advertising: an oncologist's view. (1979) (0)
Dr. Richard (Dick) Hill 1942–2021 (2021) (0)
1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing? (2015) (0)
Compound clamps down on prostate cancer (2009) (0)
Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurrence score in early breast cancer. (2014) (0)
Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): a phase II trial in men with castration resistant prostate cancer (mCRPC). (2016) (0)
In this issue (2005) (0)
REVIEW Placebo Effects in Oncology (2003) (0)
Middle East Agricultural Health Study. (1995) (0)
The role of clinical trials and their impact on breast cancer management (1998) (0)
The Impact of Special Access Programs (SAP) on Prescribing Patterns in Metastatic Castration Resistant Prostate Cancer (mCRPC) (2021) (0)
Disseminated intravascular coogulation as the presenting sign of metastatic prostate cancer (2006) (0)
Use and misuse of common terminology criteria for adverse events in cancer clinical trials (2016) (0)
Patients' perceptions of early palliative oncology care: A qualitative analysis. (2013) (0)
Pharmacoeconomics (2021) (0)
Combined modality treatment with radiation and chemotherapy: bleak house or great expectations? (1992) (0)
Abstract 537: Mechanisms by which pantoprazole, a proton pump inhibitor, enhances the activity of doxorubicin in solid tumors (2011) (0)
AQ4N, a prodrug activated under hypoxic conditions results in complementary drug distribution and increased therapeutic activity when administered with mitoxantrone or doxorubicin in solid tumors (2007) (0)
Impact of androgen deprivation therapy (ADT) on bone mineral density (BMD) over 3 years in men with nonmetastatic prostate cancer. (2012) (0)
Axillary nodes dissection in breast cancer. (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ian F. Tannock?

Ian F. Tannock is affiliated with the following schools:

Ian F. Tannock's Academic­Influence.com Rankings

Why Is Ian F. Tannock Influential?

Ian F. Tannock's Published Works

Published Works

What Schools Are Affiliated With Ian F. Tannock?

Ian F. Tannock's AcademicInfluence.com Rankings